Blackhawk’s Mindbio Therapeutics announces that research associates at the University of Auckland have been awarded $1.44 million in grants for studies of LSD microdosing in major depressive disorder

• The successful approval follows the recent successful completion of the Phase 1 LSD microdosing LSD study with 80 participants

• MindBio works exclusively on psychedelic microdosing clinical trials with research partners at the University of Auckland to develop intellectual property and novel microdosing treatments

Vancouver, British Columbia – TheNewswire – July 25, 2022 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:0YY); (OTC:BLRZF) (the “company” or “Black Hawk), a subsidiary of MindBio Therapeutics (“MindBio”) at the University of Auckland in New Zealand, have received a grant of NZ$1.44 million from the Health Research Council of New Zealand to conduct a LSD (lysergic acid diethylamide) microdosing study. perform patients with major depression.

The grant funding follows the recent successful completion of a Phase 1 clinical trial in 80 healthy participants. Data from this Phase 1 study is currently being compiled and MindBio will make further announcements as information becomes available.

MindBio is working exclusively on psychedelic microdosing clinical trials with University of Auckland research associates to develop intellectual property and novel microdosing treatments for mental illness that can be commercialized and used to treat patients in the primary health care system.

“We are proud of the work of our scientific staff and the considerable support shown is a testament to the caliber of the scientists leading the project. We are committed to developing breakthrough treatments for mental illness,” said Frederick Pels, CEO of Blackhawk Growth Corp.

About Blackhawk growth

Blackhawk is a private equity firm seeking to create significant value for its shareholders through the acquisition and development of high growth companies. It has focused its investments on the healthcare, cannabis, and cannabidiol industries in Canada and the United States. Company portfolio includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, Digital Mind Therapeutics, MindBio Therapeutics, Blum Distributors Ltd. and a stake in Gaia Grow Corp.

Please join the conversation in the Telegram group of our Blackhawk group supporters at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For more information please contact:

Frederick Pels, Chairman of the Board

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, except Statements of historical fact are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transactions and future operations of MindBio Therapeutics Pty Ltd, convey and readers will understand current expectations and plans with respect to the future cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties, which may be general or specific, leading to the possibility that expectations, forecasts, predictions, projections or conclusions may not prove to be accurate, that assumptions may not be accurate and that objectives, strategic objectives and priorities are not met. These risks and uncertainties include, but are not limited to, those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in the forward-looking information, there may be other factors that cause actions, events or results not to be as expected, estimated or intended. There can be no assurance that this information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

About the University of Auckland
The University of Auckland is the leading university of Aotearoa New Zealand, ranking 87th globally in the 2022 QS World Rankings and sixth in the Times Higher Education University Impact Rankings measure up Performance against the Sustainable Development Goals. Top-class research in all disciplines, represented by its eight faculties and two large research institutes, secures its place among the leading international research universities.